Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neurogene Inc. (NGNE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage gene therapy company, Neurogene uses current reports on Form 8-K and other filings to communicate material events related to its Rett syndrome program NGN-401, financial results and corporate presentations.
Recent 8-K filings reference press releases announcing quarterly financial results, including research and development and general and administrative expenses, as well as updates on cash resources. Other 8-Ks furnish clinical and regulatory milestones, such as positive interim data from the NGN-401 Phase 1/2 trial, dosing of the first participant in the Embolden registrational trial, completion of discussions with the FDA on the Embolden protocol, and related corporate presentations made available on the company’s website.
For users analyzing NGNE, these filings help clarify how Neurogene reports its progress in Rett syndrome, the structure and status of the Embolden trial, and key financial metrics associated with its development-stage operations. Forms 8-K also document the timing and content of public communications, including clinical data updates and preclinical findings on intracerebroventricular versus intrathecal lumbar delivery of NGN-401.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight the main points of lengthy filings, allowing readers to quickly understand the nature of each disclosure. Investors can use this page to monitor new 8-Ks and other SEC reports for NGNE, track clinical and regulatory developments, and review how Neurogene describes risks, forward-looking statements and financial condition in its official filings.
Neurogene Inc. Chief Scientific Officer Stuart Cobb reported selling 6,797 shares of common stock in three open-market transactions on March 13, 2026. The sales occurred at prices reported as weighted averages of
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on
Neurogene Inc. President and CFO Christine Mikail Cvijic reported automatic sales of common stock tied to a restricted stock unit (RSU) vesting. On March 13, 2026, a total of 4,045 shares of Neurogene common stock were sold in three open-market transactions at weighted average prices of $20.4224, $21.2451, and $22.0195 per share.
According to the disclosure, these sales were executed under the RSU award agreement, which requires the company to sell enough shares to cover the executive’s tax withholding obligations from the March 12, 2025 vesting event, with no election by the executive. After the sales, Cvijic directly owned 105,798 common shares, in addition to multiple unvested RSU awards scheduled to vest between 2026 and 2029.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported an open‑market sale of 4,800 shares of common stock on February 27, 2026 under a pre‑arranged Rule 10b5‑1 plan adopted on August 18, 2025. The weighted average sale price was $25.1096 per share, with individual trades ranging from $25.00 to $25.325. After this transaction, she and her spouse jointly hold 109,843 shares, including 21,269 restricted stock units from a March 13, 2024 grant, 20,300 restricted stock units from a March 26, 2025 grant, and 22,000 restricted stock units from a February 20, 2026 grant, plus 19,200 shares held jointly.
Neurogene Inc. announced that the U.S. FDA has granted Breakthrough Therapy designation to NGN-401, its investigational, one-time AAV9 gene therapy for Rett syndrome. The designation is based on interim Phase 1/2 data as of October 30, 2025, showing clinically meaningful, durable functional improvements across multiple Rett domains with continued skill acquisition over time.
NGN-401 uses Neurogene’s proprietary EXACT™ transgene regulation technology and is delivered via intracerebroventricular administration to broadly target the brain and nervous system. The therapy is being studied in the Embolden™ registrational trial, with dosing expected to complete in the second quarter of 2026 and additional interim Phase 1/2 data planned for mid-2026. NGN-401 also holds multiple other U.S., European and U.K. regulatory designations intended to support development for this serious rare disease.
Neurogene Inc. reported that Chief Scientific Officer Cobb Stuart acquired 16,500 shares of common stock in the form of restricted stock units. These units were granted at no cash cost and will vest in three equal annual installments starting on February 20, 2027, contingent on continued service.
After this grant, Stuart holds 37,294 restricted stock units in total, reflecting multiple prior awards. According to the footnotes, these earlier grants vest annually from March 13, 2025 through March 13, 2027 and from March 26, 2026 through March 26, 2028, with the new grant vesting through February 20, 2029.
Neurogene Inc. reported that Chief Medical Officer Jordan Julie acquired equity awards on February 20, 2026. The awards include a stock option for 29,600 shares of common stock and 4,900 restricted stock units, both subject to multi‑year vesting tied to continued service.
Neurogene Inc. reported that President and CFO Christine Mikail Cvijic received new equity awards. On February 20, 2026 she was granted a stock option for 131,900 shares of common stock at an exercise price of $0.00 per share. One quarter of this option vests on the first anniversary of the grant, with the remaining three quarters vesting in equal monthly installments through the fourth anniversary, conditioned on continued service. She also received 22,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date, also subject to continued service. Following these awards, her directly held common stock position is 114,643 shares, including previously granted restricted stock units and 24,000 shares held jointly with her spouse.
Neurogene Inc. reported that Chief Executive Officer and director Rachel McMinn acquired new equity awards. On February 20, 2026, she received a stock option covering 155,100 shares of common stock at an exercise price of